Prostaglandin E2 promotes hepatic bile acid synthesis by an E prostanoid receptor 3‐mediated hepatocyte nuclear receptor 4α/cholesterol 7α‐hydroxylase pathway in mice
Open Access
- 5 November 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 65 (3) , 999-1014
Abstract
Prostaglandin E2 (PGE2) is an important lipid mediator of inflammation. However, whether and how PGE2 regulates hepatic cholesterol metabolism remains unknown. We found that expression of the PGE2 receptor, E prostanoid receptor 3 (EP3) expression is remarkably increased in hepatocytes in response to hyperlipidemic stress. Hepatocyte‐specific deletion of EP3 receptor (EP3 hep–/– ) results in hypercholesterolemia and augments diet‐induced atherosclerosis in low‐density lipoprotein receptor knockout (Ldlr –/– ) mice. Cholesterol 7α‐hydroxylase (CYP7A1) is down‐regulated in livers of EP3hep–/–Ldlr−/− mice, leading to suppressed hepatic bile acid (BA) biosynthesis. Mechanistically, hepatic‐EP3 deficiency suppresses CYP7A1 expression by elevating protein kinase A (PKA)‐dependent Ser143 phosphorylation of hepatocyte nuclear receptor 4α (HNF4α). Disruption of the PKA‐HNF4α interaction and BA sequestration rescue impaired BA excretion and ameliorated atherosclerosis in EP3hep–/–Ldlr−/− mice. Conclusion: Our results demonstrated an unexpected role of proinflammatory mediator PGE2 in improving hepatic cholesterol metabolism through activation of the EP3‐mediated PKA/HNF4α/CYP7A1 pathway, indicating that inhibition of this pathway may be a novel therapeutic strategy for dyslipidemia and atherosclerosis. (Hepatology 2017;65:999‐1014)Keywords
Funding Information
- National Natural Science Foundation of China (91439204, 31200860, 81200615, 2014M561534, 31300944, 31371153, 31371154, 81500664)
- Ministry of Science and Technology of China (2012CB945100)
- Shanghai Committee of Science and Technology (14JC1407400, 15140902000)
- Jiangsu Collaborative Innovation Center for Cardiovascular Translational Medicine
This publication has 48 references indexed in Scilit:
- Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in miceProceedings of the National Academy of Sciences, 2012
- The acute phase response inhibits reverse cholesterol transportJournal of Lipid Research, 2010
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Prostaglandin F2αelevates blood pressure and promotes atherosclerosisProceedings of the National Academy of Sciences, 2009
- Prostaglandin E2 Via Steroidogenic Factor-1 Coordinately Regulates Transcription of Steroidogenic Genes Necessary for Estrogen Synthesis in EndometriosisThe Journal of Clinical Endocrinology & Metabolism, 2009
- Increased Inflammatory Gene Expression in ABC Transporter–Deficient MacrophagesCirculation, 2008
- A novel anti-atherogenic role for COX-2—potential mechanism for the cardiovascular side effects of COX-2 inhibitorsProstaglandins & Other Lipid Mediators, 2007
- Night eating and obesity in the EP3R-deficient mouseProceedings of the National Academy of Sciences, 2007
- Vascular wall–produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptorsJournal of Experimental Medicine, 2007
- Bile acids and cytokines inhibit the human cholesterol 7α‐hydroxylase gene via the JNK/c‐jun pathway in human liver cells†Hepatology, 2006